A case of ovarian large cell neuroendocrine carcinoma

Lee, Jung Ju; Lee, Ju Ok; Lee, Dae Hyung; Kim, Mi Jin; Lee, Doojin

doi:10.5468/kjog.2012.55.1.43

Cited by 6 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various combinations have been tried in the cases reported so far such as paclitaxel–carboplatin, cisplatin–cyclophosphamide, and etoposide–cisplatin with varying results. [ 9 ] As was seen in one of the reported cases by Jehine Feki et al, 55% in the tumor mass was appreciated following etoposide–cisplatin combination. [ 10 ]…”

Section: Discussionmentioning

confidence: 92%

Primary pure large-cell neuroendocrine carcinoma of the ovary: A rare case report

Chopra

Yadav

Jaiswal

et al. 2022

Gynecol Minim Invasive Ther

View full text Add to dashboard Cite

Primary pure large-cell neuroendocrine carcinoma is a rare entity with 17 cases reported till now. A 48-year-old, Para6 Live4, postmenopausal woman presented with complaints of pain abdomen, constipation for 6 months, and postmenopausal bleeding for 1 month. On per abdominal examination, an irregular, hard, fixed, and tender mass was felt in the pelvis corresponding to 32 weeks size gravid uterus. Her magnetic resonance imaging findings were suggestive of a large abdominopelvic mass of size 10.2 cm × 12.7 cm × 14.2 cm with inferior extension into the left adnexa and 3.1 cm × 2.2 cm × 2.1 cm right adnexal mass. Debulking surgery was done. The intraoperative findings were of a large abdominopelvic mass adhered to the sigmoid colon and retroperitoneal space. Histopathological and immunohistochemistry findings were suggestive of bilateral large-cell neuroendocrine carcinoma of ovaries with strong positive for Bcl2, CD56, NSE, PR, and P53. The patient was started on tablet etoposide as adjuvant treatment. After 5 months of primary surgery, contrast-enhanced computed tomography of the chest, abdomen, and pelvis revealed recurrence. She succumbed to her illness 6 months after primary surgery. Owing to its rarity and difficulty in diagnosis, it is suggested that all such cases should be registered at national level and critically analyzed to find the high risk and associated prognostic factors.

show abstract

Section: Discussionmentioning

confidence: 92%

Primary pure large-cell neuroendocrine carcinoma of the ovary: A rare case report

Chopra

Yadav

Jaiswal

et al. 2022

Gynecol Minim Invasive Ther

View full text Add to dashboard Cite

show abstract

“…Generally, LCNEC in the gynaecological organs affects the uterine cervix and ovary. According to the definition from the World Health Organization, primary ovarian large cell neuroendocrine carcinoma is synonymous with "undifferentiated carcinoma of the nonsmall cell neuroendocrine type" (2,3). Ovarian LCNEC is an aggressive neoplasm, and most patients die of disseminated disease within one year of primary operation even after undergoing chemotherapy (4−7).…”

Section: Discussionmentioning

confidence: 99%

Large Cell Neuroendocrine Carcinoma of the Ovary and its Skin Metastases: A case report and review of the literature Ovarian Large Cell Neuroendocrine Carcinoma

Cokmert¹,

Demir²,

Doğanay³

et al. 2014

West Indian Med J

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma in the gynaecological organs affects the uterine cervix and ovary. Large cell neuroendocrine carcinoma of the ovary is extremely rare, and prognosis is quite poor even when diagnosed at an early stage. These tumours respond poorly to standard chemotherapy regimens. The clinical observation of skin metastasis in patients with epithelial ovarian cancer is relatively uncommon, occurring in only 3.5% of patients. These lesions are observed mostly in skin of the abdominal wall adjacent to the primary ovarian tumours. Metastatic skin lesions on extremities are much more rare; it is reported that only 12% of epithelial ovarian carcinoma skin metastases occur on the limbs. Skin metastasis due to large cell neuroendocrine carcinoma of the ovary has not been previously reported. We report the case of a large cell neuroendocrine tumour of the ovary with skin metastases on extremities appearing two months after surgery in a 68-year old woman.

show abstract

“…[30]35III15/rightMucinous cystadenoma (BLM) & mucinous adenocarcinomaTAH/BSO/OM/APYesDOD 4 m37. [31]40Ia30/leftMucinous adenoma, cystadenoma (BLM) & mucinous adenocarcinomaTAH/BSO/LM/OM/AP/PALAYesNED 8 m38. [32]21Ia5/rightMucinous tumor (BLM)RSOBEP → TCDOD 5 m39.…”

Section: Introductionmentioning

confidence: 99%

Pathological features, clinical presentations and prognostic factors of ovarian large cell neuroendocrine carcinoma: a case report and review of published literature

2019

View full text Add to dashboard Cite

Background There is no consensus on the optimal chemotherapy regimen and the prognostic factors for ovarian large cell neuroendocrine carcinoma (LCNEC), a rare type of tumor. The objective of the present study is to present the case of a recent encounter of pure ovarian LCNEC and perform a brief review to summarize the clinicopathological features and prognostic factors of 57 cases of LCNEC patients that have been previously reported. Method: case presentation Eligible studies were searched for online and 57 cases with clear follow-up data were found to have been reported. We present the 58th case, which is of a 70-year-old woman with stage IIIc primary pure LCNEC of the ovary. The initial symptom of this patient was abdominal distension (more than 2 months). A recent ultrasound test showed a solid-cystic mass occupying the pelvic and abdominal cavity. She received two courses of cisplatin-etoposide chemotherapy as an adjuvant therapy. No signs of nonclinical or radiological evidence of disease recurrence was found at follow-up examinations during the first 3 months after operation. A retrospective review of these 58 cases was conducted and survival curves were estimated. Using the Kaplan-Meier method. Conclusion The patients included were aged between 18 and 80 years. A Kaplan-Meier survival curve revealed that the median overall survival was 10.000 months, while 26 (44.83%) patients died within 12 months. We compared the overall mean survival time of all patients with that of stage I patients (42.418 vs 42.047 months), which suggests that ovarian LCNEC has a very poor prognosis even at stage I. Mean survival was longer for patients who had undergone postoperative chemotherapy than for those without postoperative chemotherapy (48.082 vs 9.778 months). A small series, such as this, does not provide adequate data to establish a firm correlation between the postoperative chemotherapy and prognosis ( p = 0.176). In our review of 58 cases with ovarian LCNEC, prognosis was unfavorable in most cases. Given the rarity of LCNEC, it is highly recommended that a global medical database of ovarian LCNEC and a standard system of diagnosis and treatment is established.

show abstract

A case of ovarian large cell neuroendocrine carcinoma

Cited by 6 publications

References 8 publications

Primary pure large-cell neuroendocrine carcinoma of the ovary: A rare case report

Primary pure large-cell neuroendocrine carcinoma of the ovary: A rare case report

Large Cell Neuroendocrine Carcinoma of the Ovary and its Skin Metastases: A case report and review of the literature Ovarian Large Cell Neuroendocrine Carcinoma

Pathological features, clinical presentations and prognostic factors of ovarian large cell neuroendocrine carcinoma: a case report and review of published literature

Contact Info

Product

Resources

About